KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Cash from Investing Activities (2018 - 2025)

Historic Cash from Investing Activities for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $17.3 million.

  • Adaptive Biotechnologies' Cash from Investing Activities rose 22689.62% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.3 million, marking a year-over-year increase of 1603.43%. This contributed to the annual value of $77.8 million for FY2024, which is 3999.71% down from last year.
  • According to the latest figures from Q3 2025, Adaptive Biotechnologies' Cash from Investing Activities is $17.3 million, which was up 22689.62% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' Cash from Investing Activities ranged from a high of $93.8 million in Q1 2021 and a low of -$97.5 million during Q4 2022
  • Its 5-year average for Cash from Investing Activities is $23.0 million, with a median of $25.6 million in 2025.
  • Per our database at Business Quant, Adaptive Biotechnologies' Cash from Investing Activities tumbled by 24512.88% in 2022 and then skyrocketed by 68640.96% in 2023.
  • Over the past 5 years, Adaptive Biotechnologies' Cash from Investing Activities (Quarter) stood at $67.2 million in 2021, then tumbled by 245.13% to -$97.5 million in 2022, then soared by 103.29% to $3.2 million in 2023, then soared by 589.71% to $22.1 million in 2024, then fell by 21.86% to $17.3 million in 2025.
  • Its last three reported values are $17.3 million in Q3 2025, $3.3 million for Q2 2025, and $25.6 million during Q1 2025.